Anaptysbio (ANAB) EBITDA (2016 - 2026)

Anaptysbio has reported EBITDA for 11 years, with the latest figure at -$53.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 34.28% year-over-year to -$53.0 million; the trailing twelve-month figure through Mar 2026 stood at -$27.1 million (up 80.62% YoY), and the FY2025 full-year result was -$13.6 million, up 90.59% from the prior year.
• EBITDA for Q1 2026 stood at -$53.0 million, down from $49.5 million in the prior quarter.
• The five-year high for EBITDA was $49.5 million in Q4 2025, with the low at -$53.0 million in Q1 2026.
• Historically, EBITDA has averaged -$29.6 million across 5 years, with a median of -$38.3 million in 2022.
• Annual changes were most pronounced in 2022 — EBITDA sank 6778.74% — and 2025, when it jumped 322.79%.
• Anaptysbio's EBITDA stood at -$25.7 million in 2022, then plunged by 58.5% to -$40.7 million in 2023, then surged by 45.3% to -$22.2 million in 2024, then jumped by 322.79% to $49.5 million in 2025, then tumbled by 206.99% to -$53.0 million in 2026.
• The last three EBITDA figures came in at -$53.0 million (Q1 2026), $49.5 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.